12 Health Care Stocks Moving In Wednesday’s Intraday Session
Gainers MSP Recovery (NASDAQ:LIFW) stock moved upwards by 118.1% to $0.2 during Wednesday’s regular session. MSP Recovery’s stock…
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 275 companies made new 52-week lows.
Canopy Growth, DocGo And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mostly flat on Monday. Here are some big stocks recording losses in today’s session.
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 169 companies set new 52-week lows.
Why Avantax Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study in acromegaly.
Smucker, FuelCell Energy, Granite Ridge Resources And Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Monday. Here are some big stocks recording losses in today’s session.
IHS Holding Limited (NYSE: IHS) shares fell 15.7% to $5.01.
Why Olin Are Trading Lower By 13%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Gainers
Edible Garden AG Incorporated (NASDAQ: EDBL) surged 181.1% to $3.63.
TradeUP Acquisition Corp. (NASDAQ: UPTD) gained 148.5% to $18.14.
NIO, XPeng, MongoDB And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session.
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell
• Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in DRP-selected metastatic breast cancer patients.